Celularity, Inc. (NASDAQ:CELU) Short Interest Update

Celularity, Inc. (NASDAQ:CELU) saw a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 355,364 shares, a decline of 27.3% from the January 29th total of 488,580 shares. Based on an average daily trading volume, of 30,892 shares, the short-interest ratio is presently 11.5 days. Approximately 1.5% of the company’s shares are short sold. Approximately 1.5% of the company’s shares are short sold. Based on an average daily trading volume, of 30,892 shares, the short-interest ratio is presently 11.5 days.

Celularity Stock Performance

Celularity stock traded down $0.01 during trading on Monday, reaching $1.22. 7,275 shares of the company’s stock were exchanged, compared to its average volume of 34,387. The company’s 50-day moving average is $1.27 and its two-hundred day moving average is $1.88. The firm has a market cap of $35.18 million, a price-to-earnings ratio of -0.37 and a beta of 0.79. Celularity has a 52-week low of $1.00 and a 52-week high of $4.35.

Institutional Trading of Celularity

Several large investors have recently added to or reduced their stakes in CELU. Perennial Investment Advisors LLC purchased a new stake in Celularity during the third quarter valued at about $28,000. XTX Topco Ltd bought a new stake in shares of Celularity during the fourth quarter valued at approximately $33,000. Acadian Asset Management LLC acquired a new stake in Celularity during the first quarter valued at approximately $34,000. Jane Street Group LLC bought a new stake in shares of Celularity in the 4th quarter worth about $46,000. Finally, Bank of America Corp DE raised its position in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after purchasing an additional 35,023 shares during the last quarter. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.